logo
Share SHARE
FONT-SIZE Plus   Neg

Boston Scientific Gets CE Mark Approval For SYNERGY Stent - Quick Facts

Boston Scientific Corp. (BSX) said it received CE Mark approval for the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating.

The SYNERGY Stent is the latest innovation in drug-eluting stent technology from Boston Scientific. It is unique in that its proprietary PLGA polymer and everolimus drug coating dissipate by three months. This innovation has the potential to improve post-implant vessel healing and will eliminate long-term polymer exposure, a possible cause of late adverse events.

The SYNERGY Stent is supported by a rigorous clinical program builds on the EVOLVE six-month study results which demonstrated non-inferiority to the Boston Scientific PROMUS Element Stent for the primary angiographic endpoint of in-stent late loss, a proxy for efficacy. At 12 months, the SYNERGY Stent demonstrated a target lesion revascularization rate of 1.1 percent and a stent thrombosis rate of 0.0 percent.

The SYNERGY Stent will be available in a full range of sizes to select centers in Europe and other geographies by early 2013. This limited market release is expected to provide additional data to support the clinical and economic benefits of this novel bioabsorbable technology. A broad commercial launch of the SYNERGY Stent is planned for early 2014.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Drug major Johnson & Johnson Tuesday said it expects higher earnings and sales for its fiscal 2017, which are below market estimates. The company also reported solid fourth-quarter results, with adjusted earnings above market estimates, while sales missed their view, despite a growth. In pre-market activity on the NYSE, Johnson & Johnson shares were losing 1.68 percent. Verizon Communications Inc. (VZ) reported fourth-quarter adjusted earnings per share of $0.86 compared to $0.89, prior year. On average, 24 analysts polled by Thomson Reuters expected the company to report profit per share of $0.89 for the quarter. Analysts' estimates typically exclude special items.... German business software maker SAP AG on Tuesday raised its forecast for fiscal 2017 and 2020, after reporting higher profit and revenues in its fourth quarter. For fiscal 2017, SAP now expects non-IFRS operating profit in a range of 6.8 billion euros to 7.0 billion euros at constant currencies, compared to 6.63 billion euros in 2016.
comments powered by Disqus
Follow RTT